Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan; 132(1):52-65.

View in: PubMed

collapse authors with profiles